Financhill
Back

Blueprint Medicines Quote, Financials, Valuation and Earnings

Blueprint Medicines Price Quote

$91.68
-1.42 (-1.53%)
(Updated: April 30, 2024 at 3:45 PM ET)

Blueprint Medicines Key Stats

Buy
55
Blueprint Medicines (BPMC) is a Buy

Day range:
$91.12 - $94.91
52-week range:
$43.89 - $101.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
22.61
P/B ratio:
43.65%

Volume:
622.9K
Avg. volume:
696.1K
1-year change:
82.37%
Market cap:
$5.7B
Revenue:
$249.4M
EPS:
$-8.36

How Much Does Blueprint Medicines Make?

Is Blueprint Medicines Growing As A Company?

  • What Is Blueprint Medicines's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.86%
  • What Is Blueprint Medicines's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Blueprint Medicines Stock Price Performance

What Is Blueprint Medicines 52-Week High & Low?

Blueprint Medicines Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Blueprint Medicines?

Is Blueprint Medicines Cash Flow Positive?

  • What Is BPMC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$436.8M
  • What Is Blueprint Medicines’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $119.2M
  • What Is Blueprint Medicines’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $274M

Blueprint Medicines Return On Invested Capital

  • Is Management Doing A Good Job?
    BPMC return on invested capital is -102.67%
  • What Is Blueprint Medicines Return On Assets?
    ROA measures how assets are converting to revenues and is -43.47%
  • What Is BPMC Return On Equity?
    ROE is a measure of profitability and is -161.12%

Blueprint Medicines Earnings Date & Stock Price

Blueprint Medicines Competitors

  • Who Are Blueprint Medicines's Competitors?
    Below is a list of companies who compete with Blueprint Medicines or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Apellis Pharmaceuticals Inc (APLS)
    • Ionis Pharmaceuticals Inc (IONS)
    • Madrigal Pharmaceuticals Inc (MDGL)
    • Sarepta Therapeutics Inc (SRPT)

Blueprint Medicines Dividend Yield

Data Unavailable

Blueprint Medicines Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 11.48%
Revenue: 85.55% 7.23%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 4
Sell Recommendations: 1
Price Target: 98.06
Upside from Last Price: 5.33%

Major Shareholders

  • How many BPMC shares are owned by institutional investors?
    111M BPMC shares are owned by institutional investors
  • How many BPMC shares are owned by insiders?
    1.4M BPMC shares are owned by insiders